New computer tool aims to improve blood sugar control in hospital diabetes patients
NCT ID NCT07664293
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an electronic glucose management system (eGMS) designed to help doctors decide insulin doses for hospitalized patients with type 2 diabetes. The trial compared the eGMS to the usual insulin ordering protocol in 140 patients. The goal was to see if the eGMS could improve blood sugar control and safety.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Electronic Glucose Management System (eGMS) device
- What this could lead to
- If successful, this system could help hospital staff manage blood sugar more safely and effectively in patients with type 2 diabetes.
- What could go wrong
- This is a small, single-center completed trial. The system may not work better than standard care, and results may not apply to other hospitals or patient groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
140 people
The number who actually took part.
- Started
-
Apr 2023
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 20 years * Type 2 diabetes mellitus * Required four-times-daily subcutaneous basal-bolus insulin during admission * At least two point-of-care glucose readings \>180 mg/dL during admission Exclusion Criteria: * Type 1 diabetes mellitus * Pregnancy * Gestational diabetes * Hyperosmolar hyperglycemic state or diabetic ketoacidosis at admission * Total parenteral nutrition * Treatment with intravenous insulin infusion (insulin pump)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Far Eastern Memory Hospital
New Taipei City, 220, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mindfulness and yoga rewire diabetes habits?
- Can a vegan diet delivered online help people with type 2 diabetes?
- Tiny horses, big lessons: can ponies help kids tame diabetes?
- Gut microbes in pregnancy and infancy: a window into lifelong health?
- A blood test at 50 could flag your risk of five diseases. can an app stop them?
- Chatbot coach takes aim at diabetes risk after pregnancy